The main clinical problems that follow heart-lung transplantation are opportunist infections of the lungs and pulmonary rejection. Of 23 patients undergoing heart-lung transplantation, eight had opportunist infections and 12 had at least one episode ofpulmonary rejection. Cardiac rejection occurred in only one patient, who did not need treatment. Of the 12 patients who had pulmonary rejection, nine recovered fully after augmented immunosuppression with high dose corticosteroids, although one patient required additional low dose corticosteroids for eight months before making a full recovery. Fatal opportunist lung infection followed treatment for rejection in two patients. One patient developed obliterative bronchiolitis. Of the eight patients with opportunist infections, five had primary cytomegalovirus pneumonitis, acquired from the donor. All three patients treated with acyclovir died, whereas the two treated with hyperimmune globulin and dihydroxy proxymethylguanine recovered fully. Two patients developed Pneumoncystis carinii pneumonia, which was treated successfully in one patient with intravenous sulphadimidine and trimethoprim. The other patient died after a further episode of rejection and aspergillus bronchitis. One patient developed a tuberculous empyema. The calculated actuarial survival at one year was 78% and at two years 67-2%. Although it is still in its innovative stage heart-lung transplantation appears to have complications and results similar to those of transplantation of other organs.
Introduction
Successful human heart and lung transplantation with cyclosporin to produce immunosuppression was Clinical and experimental work suggests that obliterative bronchiolitis is related to chronic rejection57 and its incidence has fallen with greater experience in the regulation of immunotherapy. 4 We report our experience of these problems in 23 patients and describe our current management strategy for both opportunist infection and pulmonary rejection.
Patients and methods
Twenty three patients underwent heart-lung transplantation at Papworth Hospital from April 1984 to April 1987; one patient also received a liver transplant. The original diagnoses are shown in table I and details of perioperative and maintenance immunosuppression in table 2. The criteria for patient and donor selection and the operative procedure have been previously reported.8" Antibiotic prophylaxis consisted of intravenous flucloxacillin (500 mg six hourly) and ceftazidime (I geight hourly) given at induction of Clinical experience in management ofpulmonary infection and rejection in heart-lung transplant recipients 763 
TREATMENT
During episodes of rejection patients were given daily intravenous boluses of 0 5 g methyl prednisolone for three days and oral prednisolone 1 mg/kg daily reducing to zero over a two week period. One patient was treated with 10 mg of prednisolone daily for eight months. Pnewmocystis carinii pneumonia was treated with trimethoprim 15 mg/kg per day and sulphadimidine 2 g four times daily intravenously for 10 days followed by oral co-trimoxazole 3840 mg (Septrin eight tablets) daily for four weeks. '3 The first three patients with cytomegalovirus pneumonia were treated with intravenous acyclovir. From September 1986 patients who were known to be cytomegalovirus "mismatches" (that is, seronegative recipients with organs from seropositive donors) were treated prophylactically with hyperimmune globulin postoperatively. They received a weekly intramuscular injection of cytomegalovirus specific gammaglobulin until they either developed disease, seroconverted without apparent disease, or were finally discharged from hospital. It was known whether the donor was cytomegalovirus seropositive within 48 hours of surgery and the first dose was given at that time. Cytomegalovirus negative blood products were not available for use in these patients as this diagnosis was made only after surgery. Later patients with cytomegalovirus pneumonitis received intravenous DHPG (9(1,3dihydroxy-2-propoxymethyl) guanine) at a dose of 5 mg/kg for 14 days (Weilcome Foundation, Crewe).
Results

SURVIVAL AFTER TRANSPLANTATION
There were no operative deaths. Two early deaths occurred, one from tracheal dehiscence after 44 days Clinical experience in management ofpulmonary infection and rejection in heart-lung transplant recipients 765 has remained seronegative. The other seven patients acquired a primary cytomegalovirus infection within three months oftransplantation. In one patient, whose infection of the stomach and small bowel was diagnosed by gastric mucosal biopsy, infection resolved without treatment. Five patients developed cytomegalovirus pneumonitis. The first three were treated with acyclovir, the diagnosis having been made by transbronchial biopsy, but all died. In the subsequent two patients cytomegalovirus infection was suspected at an early stage on clinical grounds and because they had seroconverted. Initial transbronchial biopsy samples showed extensive alveolar damage but no inclusion bodies; later biopsy samples contained inclusion bodies. Both patients were treated with DHPG (Wellcome) and recovered fully. The ninth patient seroconverted with minimal symptoms but subsequently had four episodes of pulmonary rejection, which failed to respond to augmented immunosuppression. She developed obliterative bronchiolitis and died 30 months after transplantation.
REJECTION
Twenty episodes of pulmonary rejection were diagnosed in 12 of the 23 patients. Eight episodes occurred in the first three months, but rejection could occur at any time during follow up. On three occasions patients were symptom free; two episodes were diagnosed by "routine" transbronchial biopsy and one because of an abnormal chest radiograph. The other patients complained ofcough and breathlessness and there was often a low grade pyrexia. Wheezes were usually heard on auscultation with late inspiratory crackles. The chest radiograph was abnormal in only eight of the 20 episodes. On five occasions concurrent endomyocardial biopsy samples were normal. Transbronchial biopsy, performed on 18 occasions, confirmed the diagnosis in 16 but there were two false negatives (these two episodes responded to treatment). One patient on one occasion showed evidence of mild to moderate cardiac rejection. The remaining 105 cardiac biopsies yielded normal specimens. Table 5 gives the clinical details of these episodes of rejection. Pulmonary function was measured at the time of the first episode of rejection in 11 of the 12 patients. No measurements could be made in the other patient, in whom rejection occurred very early after surgery. There was a fall in FEV, and FVC in nine of the 11 patients, but only inconsistent changes in gas transfer were observed (table 6) .
Of the 12 patients with rejection, two developed opportunist infections and died shortly after being given augmented immunosuppression; one (No 9) died of cytomegalovirus infection one month after 
Discussion
The initial reports on combined heart-lung transplantation recorded a high perioperative mortality of 21-26%,34 largely due to bleeding from the chest wall. Four of our patients had bleeding that necessitated further surgery, but all survived. Our predicted actuarial survival of 78% at one year compares favourably with that of the Stanford group (71%)14 and is better than the worldwide experience of 50%.2
The most frequent cause of opportunist infection was cytomegalovirus, which resulted in symptomatic illness in six patients (26%). This is similar to the figures of21% in recipients ofheart-lung transplants,'5 and 34% in those receiving a heart transplant alone and those having heart-lung transplants.'6 The latter series, from Dummer et al,'6 included eight cases of cytomegalovirus pneumonia and showed a much greater incidence of pneumonia after combined heartlung transplantation (four of five patients) than after transplantation of the heart only (four of44 patients). They suggested that pulmonary rejection or greater immunosuppression might predispose to cytomegalovirus infection in the transplanted lung. In contrast to these reports, our patients with primary cytomegalovirus pneumonitis had all acquired it from the donor organs, compared with one out of three in the Standford series"3 and two out of four in the Pittsburgh series.'6 Cytomegalovirus infection from the donor organ has been described in other forms of organ transplantation.' 718 We have assumed that the cytomegalovirus infections in these patients were acquired from the donor organs rather than blood products because of the severity of the disease. Unfortunately we do not have sufficient cytomegalovirus negative blood products to cover all operations. We did not know until after the operation and after blood transfusion had taken place whether the donor was cytomegalovirus seropositive. In the larger heart transplant programme at our institution 27% of cytomegalovirus negative recipients receiving organs from cytomegalovirus negative donors have developed primary infection with the virus, presumably from blood products. The disease was much milder in these patients and there were no deaths (TG Wreghitt, personal communication). Possibly blood products were the source of the infection in some of our patients, though none of our four patients who were cytomegalovirus seronegative and received matched negative organs and so were potentially at risk only from blood product infection has so far shown seroconversion.
The problem of cytomegalovirus infection from the donor can be avoided if the donor serotype is known before the operation and seropositive donor organs are used only in seropositive recipients. New, rapid methods for measuring cytomegalovirus antibody are now available'9 and our current practice is to "match" donors and recipients for cytomegalovirus status. When cytomegalovirus "mismatch" became apparent in three patients they were treated with prophylactic hyperimmune globulin after operation, but all developed cytomegalovirus pneumonitis. Experience with hyperimmune globulin in recipients of bone marrow transplants suggests that it is not very effective. '8 The two most recent patients with cytomegalovirus infection were also treated with the antiviral agent DHPG, which has been shown to have some effect on cytomegalovirus infections in patients with bone marrow transplants and with AIDS. 20 The fact that these patients survived whereas the three treated with acyclovir died also suggests Penketh, Higenbottam, Hutter, Coutts, Stewart, Wallwork occurred within the first three months after transplantation, as noted by others, and this offers a useful guide to diagnosis of pulmonary infection early after transplantation.
Pnewnocystis carinii pneumonia was the most common infection reported by Griffiths et al4 and these authors suggested that antibiotic prophylaxis should be given to patients undergoing heart-lung transplantation. Prophylaxis has been shown to be very effective in bone marrow transplantation.2' We have not used co-trimoxazole prophylaxis routinely because of the additional risk ofbone marrow suppression in patients also receiving azathioprine. Our two patients developed infection with Pneumocystis carinii shortly after a course ofaugmented immunosuppression and a similar association with immunosuppressive treatment was seen in our patients with heart transplants in 1986.22 Our practice now is to give co-trimoxazole prophylaxis (Septrin, one tablet daily) selectively to patients who require augmented immunosuppression. The low dose of co-trimoxazole was selected because of the risk of marrow suppression. No cases of pneumocystis pneumonia in patients with either heartlung or heart transplants have occurred in the six months since this practice was instituted. For acute pneumocystis pneumonia trimethoprim was given with sulphadimidine rather than sulphamethoxazole, to minimise the risk offurther renal damage in patients receiving cyclosporin. '3 Of this small series of 23 patients, 12 had one or more episodes of pulmonary rejection. This is similar to the incidence of rejection in recipients of renal transplants given cyclosporin A and azathioprine.23 The incidence of pulmonary rejection has not been given in other series,34 largely because of the lack of any method of diagnosis short ofan open lung biopsy. It was initially thought that the heart and lungs would be rejected simultaneously, so that endomyocardial biopsy8"2 could be used to monitor rejection. It is now known that the organs are rejected independently424 and in our experience the lung is the more vulnerable organ. Transbronchial biopsy provides adequate material for diagnosis of rejection based on the histological appearance of perivascular lymphocytic infiltration. 6 We have now abandoned routine cardiac biopsy.
Recipients of transplants have an acute perception of dyspnoea, complaining of breathlessness with quite minor degrees of physiological impairment. In addition, the lung has an advantage over other transplanted organs in that physical signs can be detected and monitored easily. Any patient who develops respiratory symptoms or crackles or wheezes on auscultation undergoes lung function tests followed by bronchoscopy. A reduction in FEV, or FVC without symptoms or signs is also an indication for bronchoscopy and transbronchial lung biopsy. Our experience with patient 2 suggests that the treatment of rejection should be more prolonged if a good physiological response is not seen within a week. Careful monitoring oflung function may be used to assess the efficiency of augmented immunosuppression. We no longer give an arbitary course of two weeks of increased corticosteroids. Pulmonary function testing renders the management of heart-lung transplantation similar to that of other organ transplantation.
Obliterative bronchiolitis occurred as the sole pathological feature in only one patient in the present series and only one in that ofGriffith et al. 4 It was, however, a major complication in the Stanford series, found in half of the patients who survived the operation at a mean of 11 months after surgery.3 Only seven patients in the present series and eight in the Pittsburgh series have so far survived beyond one year, but from the Stanford experience we would have expected more cases of bronchiolitis. Close monitoring of lung function and the early diagnosis ofpulmonary rejection by transbronchial biopsy may have contributed to our low incidence of obliterative bronchiolitis.
In our unit only cytomegalovirus "matches" are now accepted. Patients who experience rejection are treated more aggressively and earlier with longer courses of corticosteroids and they are also given prophylaxis against Pneumocystis carinii pneumonia.
Heart-lung transplantation is in its infancy but as experience increases the mortality is being reduced."4
